Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $28.3M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Modig Berndt | Chief Executive Officer | Aug 14 '26 | Sale | $34.77 | 2,292 | $79,686 | 130,625 | Aug 18 11:49 AM |
| Berndt B.a,e. Modig | Director | Aug 14 '26 | Proposed Sale | $34.04 | 2,292 | $78,020 | — | Aug 14 04:33 PM |
| Modig Berndt | Chief Executive Officer | Jul 13 '26 | Sale | $34.97 | 2,292 | $80,154 | 132,917 | Jul 15 01:08 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.